Title : Treatment of intractable acneiform rash caused by erlotinib: A case report and literature review
Abstract:
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) widely used in targeted therapy for advanced non-small cell lung cancer. Its most common skin toxicity is acneiform rash, characterized by erythema, papules and pustules with varying degrees of pruritus. Although the skin lesions of most patients are not serious and can be significantly improved in the short term after drug withdrawal, it is undeniable that any additional symptoms under tumor torture will be unbearable for the patient's body and mind. Therefore, it is essential to provide timely and effective treatment. We report a case of refractory scalp acneiform rash caused by erlotinib combined with fungal and bacterial infection, and achieved good results after treatment with crisaborole.
